Taken together, these findings highlight the potential of targeting PLK1 as a synergistic strategy with EGFR-TKIs, underscoring the therapeutic value of combining PLK1 inhibitors with EGFR-TKIs for treating NSCLC patients with various EGFR mutations, including those harboring secondary mutations. This evidence concerns the gene PLK1 and non-small cell lung carcinoma.